技術指標
指標
數值
方向
MACD(12,26,9)
-0.401
中性
RSI(14)
49.258
中性
STOCH(KDJ)(9,3,3)
30.665
賣出
ATR(14)
16.934
低波動
CCI(14)
-144.735
賣出
Williams %R
73.424
賣出
TRIX(12,20)
0.287
賣出
StochRSI(14)
2.458
超賣
搜尋
Regeneron Pharmaceuticals Inc
REGN添加自選
651.870USD
+0.690+0.11%
收盤 07-23 16:00（美東）報價延遲15分鐘
68.45B總市值
15.34本益比TTM
關鍵數據
646.480今開
655.200最高
1.00成交量
15.34本益比TTM
11.60本益比動
3.580股利TTM
0.00%換手率
651.180昨收
637.800最低
101.00成交額
15.51本益比靜
2.18市淨率
0.55%股息率 TTM
11.40%ROA
821.11052週最高
-0.00量比
4.41B淨利潤
105.00M總股本
42.4810每股盈餘TTM
0.26Beta
14.69%ROE
476.48752週最低
2.67%振幅
81.43%毛利率
68.45B總市值
2.56回報/風險
1.74%風險率
TradingKey Regeneron Pharmaceuticals Inc股票評分
單位: USD 更新時間: 2026-07-23操作建議
Regeneron Pharmaceuticals Inc當前公司基本面數據相對健康，增長潛力很大。當前估值合理，在藥品行業排名7/155位。機構持股佔比非常高，近一月多位分析師給出公司評級為買入。最高目標價為816.02。中期看，股價處於下降通道。近一個月，市場表現較強，基本面評分較高，但較強的走勢沒有得到技術面的印證。目前股價在壓力位和支撐位之間，可以做區間波段操作。
Regeneron Pharmaceuticals Inc評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
公司輿情
過去24小時
熱度
43°C
過冷
過熱
中性
Regeneron Pharmaceuticals Inc亮點
亮點風險
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
估值低估
公司最新PE估值15.35，處於3年歷史低位
機構減倉
最新機構持股94.67M股，環比減少1.74%
梅森·霍金斯持倉
明星投資者梅森·霍金斯持倉，最新持倉160.58K股
活躍度降低
近期活躍度降低，過去20天平均換手率-0.16
分析師目標
基於
31
分析師
買入
評級
816.016
目標均價
+20.86%
漲幅空間
Regeneron Pharmaceuticals Inc新聞
即將為您帶來更多新聞，敬請期待。 。 。
收益預測
分析師評級
基於
31
分析師
買入
評級
816.016
目標均價
+20.86%
漲幅空間
強力買入
買入
持有
賣出
強力賣出
同行比較
160
總數
6
中位數
9
平均值
公司名稱
評級分佈
分析師數
Regeneron Pharmaceuticals Inc
REGN
31
Biogen Inc
BIIB
38
Amgen Inc
AMGN
37
Eli Lilly and Co
LLY
34
艾伯維
ABBV
33
輝瑞
PFE
32
1
2
3
...
32
技術指標
移動平均線
指標
數值
方向
MA5
665.424
賣出
MA10
665.424
賣出
MA20
654.925
賣出
MA50
641.676
買入
MA100
694.571
賣出
MA200
705.783
賣出
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
Regeneron Pharmaceuticals Inc簡介
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
公司代碼REGN
公司Regeneron Pharmaceuticals Inc
CEOSchleifer (Leonard S)
網址https://www.regeneron.com/
公司股東
相關品種
+1.95%
+1.46%
-0.85%
+1.43%
+2.37%
+2.01%
+1.49%
+0.38%
0.00%
+0.71%
+1.27%
+0.15%
-0.94%
-0.03%
+1.31%
0.00%
+8.61%
-0.21%
+2.45%熱門品種
51885.200
+161.200 (+0.31%)
28449.200
-128.800 (-0.45%)
7420.100
+0.200 (+0.00%)
14996.000
-105.000 (-0.69%)
64877.000
-494.000 (-0.76%)
6243.300
+27.600 (+0.44%)
89.603
-2.509 (-2.72%)
321.680
-4.210 (-1.29%)
208.770
-3.290 (-1.55%)
4053.810
+4.440 (+0.11%)
常見問題
Regeneron Pharmaceuticals Inc(REGN)的當前股價是多少？
Regeneron Pharmaceuticals Inc(REGN)的當前股價是 651.87。
Regeneron Pharmaceuticals Inc 的股票代碼是什麼？
Regeneron Pharmaceuticals Inc的股票代碼是REGN。
Regeneron Pharmaceuticals Inc股票的52週最高點是多少？
Regeneron Pharmaceuticals Inc股票的52週最高點是821.11。
Regeneron Pharmaceuticals Inc股票的52週最低點是多少？
Regeneron Pharmaceuticals Inc股票的52週最低點是476.49。
Regeneron Pharmaceuticals Inc的市值是多少？
Regeneron Pharmaceuticals Inc的市值是68.45B。
現在Regeneron Pharmaceuticals Inc(REGN)的股票是買入、持有還是賣出？
根據分析師評級，Regeneron Pharmaceuticals Inc(REGN)的總體評級為買入，目標價格為816.02。
Regeneron Pharmaceuticals Inc(REGN)股票的每股收益（EPS TTM）是多少
Regeneron Pharmaceuticals Inc(REGN)股票的每股收益（EPS TTM）是43.07。